Teva Receives FDA Acceptance of Its New Drug Application for BDP Nasal HFA for the Treatment of Allergic Rhinitis
Links shared publicly online about this topic.
- 86total visits
Teva Receives FDA Acceptance of Its New Drug Application for BDP Nasal HFA for the Treatment of Allergic Rhinitis
BDP Nasal HFA (beclomethasone dipropionate hydrofluoroalkane) is a new drug formulation in development for the treatment of allergic rhinitis. BDP Nasal HFA information includes news, clinical trial results and side effects.
View full resource at drugs.com
Tags: Allergies, Seasonal Allergy, Nose, Drug, Clinical Trial, FDA, News
Most Recently Shared on August 9, 2011 at 1:02 am By:
Teva Receives FDA Acceptance of Its New Drug Application for BDP Nasal HFA for the Treatment of Allergic R... http://bit.ly/npLr9E #drug
NDA Accepted for BDP Nasal HFA for Allergic Rhinitis - MPR
empr.com — “Teva Pharmaceutical Industries Ltd. announced that the FDA has accepted its new drug application (NDA) for BDP Nasal HFA (beclomethasone dipropionate hydrofluoroalkane) for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) after its submission in May 2011.” View full resource at empr.com
Most Recently Shared on August 8, 2011 at 2:40 pm By:
MPR News: NDA Accepted for BDP Nasal HFA for Allergic Rhinitis: Teva Pharmaceutical Industries Ltd. announced th... http://bit.ly/qzxmqp
Advertisement
